Redhill Biopharma (RDHL) to Release Quarterly Earnings on Thursday

Redhill Biopharma (NASDAQ:RDHL) is expected to announce its H2 24/25 results before the market opens on Thursday, April 9th. Analysts expect the company to announce earnings of ($474.2857) per share and revenue of $24.5140 million for the quarter. Investors can find conference call details on the company’s upcoming H2 24/25 earning report page for the latest details on the call scheduled for Wednesday, April 15, 2026 at 6:00 PM ET.

Redhill Biopharma Trading Down 3.5%

NASDAQ RDHL opened at $0.80 on Wednesday. The company has a market cap of $4.09 million, a PE ratio of 0.00 and a beta of 4.93. Redhill Biopharma has a 12 month low of $0.71 and a 12 month high of $3.31. The stock has a 50 day moving average of $0.95 and a 200-day moving average of $1.22.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Redhill Biopharma in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Redhill Biopharma presently has an average rating of “Sell”.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.